Cinacalcet treatment of primary hyperparathyroidism: Biochemical and bone densitometric outcomes in a five-year study

Munro Peacock, Michael A. Bolognese, Michael Borofsky, Simona Scumpia, Lulu Ren Sterling, Sunfa Cheng, Dolores Shoback

Research output: Contribution to journalArticle

126 Citations (Scopus)

Abstract

Context: Primary hyperparathyroidism (PHPT) is characterized by chronically elevated serum calcium and inappropriately normal or increased PTH. Objective: Our objective was to evaluate long-term tolerability, safety, and efficacy of cinacalcet in PHPT patients. Design and Setting: A 4.5-yr open-label extension study was conducted at 14 study centers in the United States. Patients or Other Participants: Forty-five subjects with PHPT from a double-blind, placebo-controlled, 1-yr trial were continued into this study. Interventions: After the parent study, all subjects were treated with 30 mg cinacalcet twice daily, increasing to 50 mg twice daily during the 12-wk titration if serum calcium levels were 10.3 mg/dl or higher and then maintained on cinacalcet for up to 4.5 yr. Main Outcome Measures: Assessments included serum calcium, PTH, phosphate and alkaline phosphatase, and areal bone mineral density (aBMD). Vital signs, safety chemistries and hematology, and adverse events were monitored throughout. Results: Compared with baseline, cinacalcet treatment improved biochemical measures of PHPT including reducing serum calcium and PTH and increasing serum phosphate with slight increases in alkaline phosphatase. No changes in z-scores of a BMD at spine, hip, or wrist were seen with annual percent changes, consistent with reports for untreated postmenopausal women or PHPT patients. Safety biochemistries remained normal, and adverse events (most commonly arthralgia, myalgia, diarrhea, respiratory infection, and nausea) were mild to moderate in severity. Conclusions: Treatment of PHPT patients with cinacalcet for up to 5.5 yr maintained normocalcemia, reduced plasma PTH, increased serum phosphate and alkaline phosphatase with no significant effects on aBMD, and was well tolerated.

Original languageEnglish
Pages (from-to)4860-4867
Number of pages8
JournalJournal of Clinical Endocrinology and Metabolism
Volume94
Issue number12
DOIs
StatePublished - Dec 2009

Fingerprint

Primary Hyperparathyroidism
Bone
Bone and Bones
Calcium
Alkaline Phosphatase
Serum
Phosphates
Minerals
Safety
Bone Density
Therapeutics
Biochemistry
Outcome Assessment (Health Care)
Titration
Vital Signs
Myalgia
Arthralgia
Hematology
Labels
Wrist

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Endocrinology
  • Biochemistry, medical
  • Endocrinology, Diabetes and Metabolism

Cite this

Cinacalcet treatment of primary hyperparathyroidism : Biochemical and bone densitometric outcomes in a five-year study. / Peacock, Munro; Bolognese, Michael A.; Borofsky, Michael; Scumpia, Simona; Sterling, Lulu Ren; Cheng, Sunfa; Shoback, Dolores.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 94, No. 12, 12.2009, p. 4860-4867.

Research output: Contribution to journalArticle

Peacock, Munro ; Bolognese, Michael A. ; Borofsky, Michael ; Scumpia, Simona ; Sterling, Lulu Ren ; Cheng, Sunfa ; Shoback, Dolores. / Cinacalcet treatment of primary hyperparathyroidism : Biochemical and bone densitometric outcomes in a five-year study. In: Journal of Clinical Endocrinology and Metabolism. 2009 ; Vol. 94, No. 12. pp. 4860-4867.
@article{41e2c8436d324bcaa2ed1f3717ff8b3a,
title = "Cinacalcet treatment of primary hyperparathyroidism: Biochemical and bone densitometric outcomes in a five-year study",
abstract = "Context: Primary hyperparathyroidism (PHPT) is characterized by chronically elevated serum calcium and inappropriately normal or increased PTH. Objective: Our objective was to evaluate long-term tolerability, safety, and efficacy of cinacalcet in PHPT patients. Design and Setting: A 4.5-yr open-label extension study was conducted at 14 study centers in the United States. Patients or Other Participants: Forty-five subjects with PHPT from a double-blind, placebo-controlled, 1-yr trial were continued into this study. Interventions: After the parent study, all subjects were treated with 30 mg cinacalcet twice daily, increasing to 50 mg twice daily during the 12-wk titration if serum calcium levels were 10.3 mg/dl or higher and then maintained on cinacalcet for up to 4.5 yr. Main Outcome Measures: Assessments included serum calcium, PTH, phosphate and alkaline phosphatase, and areal bone mineral density (aBMD). Vital signs, safety chemistries and hematology, and adverse events were monitored throughout. Results: Compared with baseline, cinacalcet treatment improved biochemical measures of PHPT including reducing serum calcium and PTH and increasing serum phosphate with slight increases in alkaline phosphatase. No changes in z-scores of a BMD at spine, hip, or wrist were seen with annual percent changes, consistent with reports for untreated postmenopausal women or PHPT patients. Safety biochemistries remained normal, and adverse events (most commonly arthralgia, myalgia, diarrhea, respiratory infection, and nausea) were mild to moderate in severity. Conclusions: Treatment of PHPT patients with cinacalcet for up to 5.5 yr maintained normocalcemia, reduced plasma PTH, increased serum phosphate and alkaline phosphatase with no significant effects on aBMD, and was well tolerated.",
author = "Munro Peacock and Bolognese, {Michael A.} and Michael Borofsky and Simona Scumpia and Sterling, {Lulu Ren} and Sunfa Cheng and Dolores Shoback",
year = "2009",
month = "12",
doi = "10.1210/jc.2009-1472",
language = "English",
volume = "94",
pages = "4860--4867",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "12",

}

TY - JOUR

T1 - Cinacalcet treatment of primary hyperparathyroidism

T2 - Biochemical and bone densitometric outcomes in a five-year study

AU - Peacock, Munro

AU - Bolognese, Michael A.

AU - Borofsky, Michael

AU - Scumpia, Simona

AU - Sterling, Lulu Ren

AU - Cheng, Sunfa

AU - Shoback, Dolores

PY - 2009/12

Y1 - 2009/12

N2 - Context: Primary hyperparathyroidism (PHPT) is characterized by chronically elevated serum calcium and inappropriately normal or increased PTH. Objective: Our objective was to evaluate long-term tolerability, safety, and efficacy of cinacalcet in PHPT patients. Design and Setting: A 4.5-yr open-label extension study was conducted at 14 study centers in the United States. Patients or Other Participants: Forty-five subjects with PHPT from a double-blind, placebo-controlled, 1-yr trial were continued into this study. Interventions: After the parent study, all subjects were treated with 30 mg cinacalcet twice daily, increasing to 50 mg twice daily during the 12-wk titration if serum calcium levels were 10.3 mg/dl or higher and then maintained on cinacalcet for up to 4.5 yr. Main Outcome Measures: Assessments included serum calcium, PTH, phosphate and alkaline phosphatase, and areal bone mineral density (aBMD). Vital signs, safety chemistries and hematology, and adverse events were monitored throughout. Results: Compared with baseline, cinacalcet treatment improved biochemical measures of PHPT including reducing serum calcium and PTH and increasing serum phosphate with slight increases in alkaline phosphatase. No changes in z-scores of a BMD at spine, hip, or wrist were seen with annual percent changes, consistent with reports for untreated postmenopausal women or PHPT patients. Safety biochemistries remained normal, and adverse events (most commonly arthralgia, myalgia, diarrhea, respiratory infection, and nausea) were mild to moderate in severity. Conclusions: Treatment of PHPT patients with cinacalcet for up to 5.5 yr maintained normocalcemia, reduced plasma PTH, increased serum phosphate and alkaline phosphatase with no significant effects on aBMD, and was well tolerated.

AB - Context: Primary hyperparathyroidism (PHPT) is characterized by chronically elevated serum calcium and inappropriately normal or increased PTH. Objective: Our objective was to evaluate long-term tolerability, safety, and efficacy of cinacalcet in PHPT patients. Design and Setting: A 4.5-yr open-label extension study was conducted at 14 study centers in the United States. Patients or Other Participants: Forty-five subjects with PHPT from a double-blind, placebo-controlled, 1-yr trial were continued into this study. Interventions: After the parent study, all subjects were treated with 30 mg cinacalcet twice daily, increasing to 50 mg twice daily during the 12-wk titration if serum calcium levels were 10.3 mg/dl or higher and then maintained on cinacalcet for up to 4.5 yr. Main Outcome Measures: Assessments included serum calcium, PTH, phosphate and alkaline phosphatase, and areal bone mineral density (aBMD). Vital signs, safety chemistries and hematology, and adverse events were monitored throughout. Results: Compared with baseline, cinacalcet treatment improved biochemical measures of PHPT including reducing serum calcium and PTH and increasing serum phosphate with slight increases in alkaline phosphatase. No changes in z-scores of a BMD at spine, hip, or wrist were seen with annual percent changes, consistent with reports for untreated postmenopausal women or PHPT patients. Safety biochemistries remained normal, and adverse events (most commonly arthralgia, myalgia, diarrhea, respiratory infection, and nausea) were mild to moderate in severity. Conclusions: Treatment of PHPT patients with cinacalcet for up to 5.5 yr maintained normocalcemia, reduced plasma PTH, increased serum phosphate and alkaline phosphatase with no significant effects on aBMD, and was well tolerated.

UR - http://www.scopus.com/inward/record.url?scp=73249115608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73249115608&partnerID=8YFLogxK

U2 - 10.1210/jc.2009-1472

DO - 10.1210/jc.2009-1472

M3 - Article

C2 - 19837909

AN - SCOPUS:73249115608

VL - 94

SP - 4860

EP - 4867

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 12

ER -